Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance

• US 20110070298A1
• Filed: 05/22/2009
• Published: 03/24/2011
• Est. Priority Date: 06/05/2008
• Status: Abandoned Application

• Current Assignee: Immunovaccine Technologies, Inc.
• Original Assignee: Immunovaccine Technologies, Inc.
• Inventors: Mansour, Marc, MacDonald, Lisa Diana, Karkada, Mohan, Fuentes-Ortega, Antar, Sammatur, Leeladhar, Weir, Genevieve Mary
• Application Number:
  US12/992,512
• Publication Number:
  US 20110070298A1
• Time in Patent Office: Days
• US Class Current: 424/450
• CPC Class Codes: A61K 2039/55505 Inorganic adjuvants
• CPC Class Codes: A61K 2039/55544 Bacterial toxins
• CPC Class Codes: A61K 2039/55555 Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
• CPC Class Codes: A61K 2039/55561 CpG containing adjuvants; Oligonucleotide containing adjuvants
• CPC Class Codes: A61K 2039/55566 Emulsions, e.g. Freund's adjuvant, MF59
• CPC Class Codes: A61K 2039/575 humoral response
• CPC Class Codes: A61K 31/785 Polymers containing nitrogen
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/0007 Nervous system antigens; Prions
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 47/06 Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/107 Emulsions ; Emulsion preconcentrates; Micelles composition of emulsions A61K47/00
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/16 for influenza or rhinoviruses
• CPC Class Codes: A61P 31/20 for DNA viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C12N 2710/20034 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/16134 : Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention provides a composition comprising: an antigen; liposomes; a polyI:C polynucleotide; and a carrier comprising a continuous phase of a hydrophobic substance. Methods for making and using the compositions are also provided.

Claims

1. A composition comprising:

(a) an antigen;

(b) liposomes;

(c) a polyI;

C polynucleotide; and

(d) a carrier comprising a continuous phase of a hydrophobic substance.

2. The composition according to claim 1, wherein the polyI:

C polynucleotide comprises RNA or DNA.

3. The composition according to claim 1, wherein the polyI:

C polynucleotide comprises RNA and DNA.

4. The composition according to claim 1, wherein the polyI:

C polynucleotide is a homopolymer or a heteropolymer.

5. The composition according to claim 1, wherein the polyI:

C polynucleotide comprises a homopolymeric polyI;

C polynucleotide and a heteropolymeric polyI;

C polynucleotide.

11. A method comprising administering the composition according to claim 1 to a subject in need thereof.

12. The method according to claim 11, which is a method for inducing an antibody response and/or cell-mediated immune response to said antigen in said subject.

13. The method according to claim 11, which is a method for the treatment and/or prevention of a disease caused by a bacteria, a virus, a fungus, a parasite, an allergen or a tumor cell that expresses the antigen.

14. The method according to claim 13, wherein the treatment and/or prevention comprises inducing an antibody and/or a cell mediated immune response to the antigen in the subject, wherein the subject has or is at risk of developing a viral infection.

15. The method according to claim 14, wherein the viral infection is an influenza virus infection.

16. The method according to claim 13, wherein the treatment and/or prevention comprises inducing an antibody and/or a cell mediated immune response to the antigen in the subject, wherein the subject has or is at risk of developing cancer.

17. The method according to claim 11, which is a method for the treatment and/or prevention of a neurodegenerative disease, wherein the neurodegenerative disease is associated with expression of the antigen.

18. The method according to claim 17, wherein the neurodegenerative disease is Alzheimer'"'"'s disease.

19. The method according to claim 11, wherein the composition induces an immune response in the subject that is at least 1.5×

higher relative to a response induced by a control composition.

20. The method according to claim 19, wherein the composition induces an immune response in the subject that is at least 5×

higher relative to a response induced by a control composition.

21. The method according to claim 11, wherein the composition is administered via a route that is nasal, oropharyngeal, ocular, oral, rectal, sublingual, genitourinary mucosa, intranasal, oropharyngeal, intratracheal, intrapulmonary, transdermal, transpulmonary, intraarterial, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous or submucosal.

6. A method for making a composition, said method comprising combining, in any order:

a) an antigen;

(b) liposomes;

(c) a polyI;

C polynucleotide; and

(d) a carrier comprising a continuous phase of a hydrophobic substance.

7. The method according to claim 6, wherein said antigen is encapsulated in said liposomes.

8. The method according to claim 6, wherein said polyI:

C polynucleotide is encapsulated in said liposomes.

9. The method according to claim 6, wherein said polyI:

C polynucleotide is added outside said liposomes.

10. A composition prepared according to the method of claim 6.